Menu
Search
|

Menu

Close
X

Corcept Therapeutics Inc CORT.OQ (NASDAQ Stock Exchange Capital Market)

12.52 USD
-0.15 (-1.18%)
As of 3:59 PM EST
chart
Previous Close 12.67
Open 12.68
Volume 266,548
3m Avg Volume 351,926
Today’s High 13.14
Today’s Low 12.48
52 Week High 25.92
52 Week Low 11.22
Shares Outstanding (mil) 115.47
Market Capitalization (mil) 1,463.03
Forward P/E 8.74
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
184
FY17
159
FY16
81
FY15
50
EPS (USD)
FY18
0.420
FY17
1.278
FY16
0.069
FY15
-0.062
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
8.74
29.57
Price to Sales (TTM)
vs sector
6.16
15.43
Price to Book (MRQ)
vs sector
5.67
4.06
Price to Cash Flow (TTM)
vs sector
7.90
21.23
Total Debt to Equity (MRQ)
vs sector
0.00
14.84
LT Debt to Equity (MRQ)
vs sector
0.00
11.13
Return on Investment (TTM)
vs sector
106.96
12.77
Return on Equity (TTM)
vs sector
106.96
14.47

EXECUTIVE LEADERSHIP

James Wilson
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Joseph Belanoff
President, Chief Executive Officer, Director, Since 2014
Salary: $647,333.00
Bonus: $702,000.00
Gary Robb
Chief Financial Officer, Secretary, Since 2014
Salary: $397,929.00
Bonus: $320,000.00
Sean Maduck
Senior Vice President - Commercial, Since 2016
Salary: $397,917.00
Bonus: $320,000.00
Robert Fishman
Chief Medical Officer, Since 2015
Salary: $427,107.00
Bonus: $171,672.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

149 Commonwealth Dr
MENLO PARK   CA   94025-1133

Phone: +1650.3273270

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

SPONSORED STORIES